Literature DB >> 12447186

Primary lung carcinoma after heart or lung transplantation: management and outcome.

A C Anyanwu1, E R Townsend, N R Banner, M Burke, A Khaghani, M H Yacoub.   

Abstract

OBJECTIVE: We sought to examine our management and outcome of lung carcinoma occurring after thoracic organ transplantation.
METHODS: We performed a retrospective review of cases of primary lung carcinoma diagnosed between 1990 and 2000 in patients who have previously undergone thoracic transplantation at our institution.
RESULTS: Seventeen patients were identified (1 lung and 16 heart transplants). Median time from transplantation to diagnosis of lung carcinoma was 89 months (range, 46-138 months). Predominant presentation was as an incidental finding at chest radiography (13/17). All patients had smoked cigarettes before transplantation, with 5 continuing to smoke after transplantation. Histologic types were squamous (n = 11), adenocarcinoma (n = 3), small cell (n = 2), and undifferentiated (n = 1). Revised International Union Against Cancer (UICC) clinical stage at the time of diagnosis was stage I or II in 11 of 17 patients. Of these, 9 underwent surgical resection; 2 patients unfit for surgical intervention had radiotherapy. Surgical procedures were lobectomy (n = 5), wedge excision (n = 3), and no resection (n = 1). Median survival after diagnosis was 12 months for all patients and 24 months if the tumor was resected. Six patients who had surgical resection subsequently died (survival of 2, 9, 21, 21, 36, and 67 months); 2 remain alive after 12 and 54 months, respectively.
CONCLUSIONS: When possible, surgical intervention should be undertaken for early stage lung cancer occurring after thoracic transplantation because medium-term survival is achievable. Sublobar excisions and definitive radiotherapy should be considered if comorbidity prevents optimal surgical treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12447186     DOI: 10.1067/mtc.2002.124885

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

1.  [Primary lung cancer in Chinese renal transplant recipients: a single-center analysis].

Authors:  Shu-Xin Zhang; Yang Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-06-20

2.  Primary non-small cell lung cancer in a transplanted lung treated with stereotactic body radiation therapy. A case study.

Authors:  F Oskan; U Ganswindt; C Belka; F Manapov
Journal:  Strahlenther Onkol       Date:  2014-02-07       Impact factor: 3.621

Review 3.  Malignancy after renal transplantation: the role of immunosuppression.

Authors:  Inés Rama; Josep M Grinyó
Journal:  Nat Rev Nephrol       Date:  2010-09       Impact factor: 28.314

4.  Dynamic tumor-tracking stereotactic body radiation therapy for a solitary tumor in a transplanted organ: two case reports.

Authors:  Shun Okabayashi; Yukinori Matsuo; Noriko Kishi; Hideki Hanazawa; Takashi Mizowaki
Journal:  Int Cancer Conf J       Date:  2020-06-29

5.  Lung cancer treatment outcomes in recipients of lung transplant.

Authors:  Lingling Du; Nathan A Pennell; Paul Elson; Nooshin Hashemi-Sadraei
Journal:  Transl Lung Cancer Res       Date:  2015-12

6.  Sphere culture of murine lung cancer cell lines are enriched with cancer initiating cells.

Authors:  Brian J Morrison; Jason C Steel; John C Morris
Journal:  PLoS One       Date:  2012-11-13       Impact factor: 3.240

7.  Successful resection of oesophageal adenocarcinoma 16 years after heart transplantation-a case report.

Authors:  Filip Eckerström; Marie Maagaard; Hans K Pilegaard
Journal:  Int J Surg Case Rep       Date:  2016-02-12

Review 8.  [Bronchogenic carcinoma after lung transplantation: a case report and literature review].

Authors:  Yeming Wang; Jingyu Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-01

9.  Mediastinal irradiation in a patient affected by lung carcinoma after heart transplantation: Helical tomotherapy versus three dimensional conformal radiotherapy.

Authors:  Francesca M Giugliano; Vincenzo Iorio; Fabrizio Cammarota; Diego Toledo; Rossana Senese; Ferdinando Francomacaro; Matteo Muto; Paolo Muto
Journal:  Thorac Cancer       Date:  2016-03-11       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.